Evaluation of the effect of capsule of date palm pollen in infertile women with polycystic ovary syndrome

Clinical trial comparison of the effect of capsule of date palm pollen with clomiphene citrate compared with clomiphene citrate only, on the levels of hormones in clomiphene citrate resistant infertile women with polycystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017082016911N4

Enrollment

100

Registered

2017-11-03

Start date

2016-11-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Polycystic ovary syndrome. Condition 2: Infertility due to PCO. Polycystic ovarian syndrome Female infertility associated with anovulation

Interventions

Intervention 1: Date Palm pollen capsule, 2 grams daily from day 5 to end of the cycle and Clomiphene citrate, 150 ml grams daily from day 5 to 9 of the menstrual cycle. Intervention 2: Placebo 2 gram

Treatment - Drugs

Placebo

Date Palm pollen capsule, 2 grams daily from day 5 to end of the cycle and Clomiphene citrate, 150 ml grams daily from day 5 to 9 of the menstrual cycle.

Placebo 2 grams daily, from day 5 to the end of the cycle and Clomiphene citrate, 150 ml grams daily from day 5 to 9 of the menstrual cycle.

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Clomiphene Citrate resistant infertile women with polycystic ovary syndrome Exclusion criteria: Having no desire to cooperate; Having allergy to date palm pollen; Interrupt treatment in ovulation period; Not using Clomiphene or date palm pollen capsule; allergic to date palm pollen; having chronic disease(Heart, respiratory, kidney and digestive diseases); using other herbal drugs that affect infertility

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Prolactine. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Progestrone. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Gonadotropines. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Testestrone. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.	—

Measure

Time frame

Prolactine. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Progestrone. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Gonadotropines. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.;Testestrone. Timepoint: Before and During intervention in Days 3 and 21 of cycle. Method of measurement: Blood Sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Alsadat Hadigheh

Shiraz University of Medical Sciences

maryam.hadigheh@gmail.com+98 71 3647 4255

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026